BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced that on December 18, 2025 its compensation committee approved inducement restricted stock unit grants to 9 new employees totaling 29,472 shares of common stock.

Vesting: one‑quarter of each award vests on November 16, 2026, then one‑twelfth of the remaining shares vests quarterly thereafter, subject to continued employment. Awards were granted under the company’s equity plan adopted November 2019 and amended in February and December 2023, and cited Nasdaq Listing Rule 5635(c)(4) as the inducement basis.

Key Figures

Inducement RSUs granted 29,472 shares Aggregate restricted stock units for 9 new employees on Dec 18, 2025

New employees 9 Employees receiving inducement restricted stock unit grants

Initial vesting date November 16, 2026 One-fourth of RSU shares vest, subject to continued employment

Subsequent vesting schedule One-twelfth quarterly Remaining RSU shares vest quarterly after initial vesting date

Market Reality Check

$76.53 Last Close

Volume Volume 4,372,788 vs 20-day average 2,159,278 (relative volume 2.03x) before this filing. high

Technical Price 76.3 was trading above the 200-day MA of 48.11 prior to the inducement grant news.

Peers on Argus

Peers in Biotechnology showed mixed moves: BMRN +11.67%, IONS +2.28%, EXEL +3.6%, SMMT +3.85%, while ASND was -0.34%. No sector momentum flag was triggered.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 25	Investor conferences	Neutral	-0.5%	Management participation in two December healthcare investor conferences and webcasts.
Nov 19	Inducement grants	Neutral	-1.4%	Inducement RSU grants to 12 new employees under Nasdaq Rule 5635(c)(4).
Nov 04	Investor conferences	Neutral	-1.0%	Announcements of fireside chats at two November 2025 investor conferences.
Nov 03	Clinical data posters	Positive	-1.1%	ATTRibute-CM acoramidis data with mortality, hospitalization and biomarker benefits.
Oct 29	Earnings & updates	Positive	+3.3%	Q3 2025 results, Attruby sales, cash position, and positive FORTIFY/CALIBRATE data.

Pattern Detected

Recent news has mostly been conferences and routine compensation/inducement updates, with the stock tending to trade down on these neutral announcements, while clearly positive financial and clinical updates have coincided with an upward move.

Recent Company History

Over the last few months, BridgeBio has reported multiple investor conference participations, inducement equity grants under Nasdaq Rule 5635(c)(4), major clinical data, and Q3 2025 financial results. The ATTRibute-CM presentations highlighted benefits of acoramidis, while earnings showed $120.7M revenue and strong Attruby sales, with $645.9M in cash and securities. These positive fundamentals and clinical milestones contrast with modest negative reactions to routine conference and inducement news leading up to the current grant announcement.

Market Pulse Summary

This announcement details inducement grants of 29,472 restricted stock unit shares to 9 new employees under Nasdaq Listing Rule 5635(c)(4), with vesting beginning on November 16, 2026 and continuing quarterly thereafter. It reflects ongoing hiring and use of equity-based compensation rather than a change in business fundamentals. In context, prior months featured more material drivers such as Q3 2025 financial results and important clinical data updates.

Key Terms

restricted stock units financial

"approved equity grants to 9 new employees in restricted stock units for an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 9 new employees in restricted stock units for an aggregate of 29,472 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com 

FAQ

What did BridgeBio (BBIO) announce on December 22, 2025 about employee equity grants?

BridgeBio announced that on December 18, 2025 it approved inducement RSU grants to 9 new employees totaling 29,472 shares.

How do the BridgeBio (BBIO) inducement RSUs vest and when does vesting start?

Vesting begins with one‑quarter of each award on November 16, 2026, then one‑twelfth of the remainder vests quarterly thereafter, subject to continued employment.

Under what authority were the BridgeBio (BBIO) inducement awards granted?

The awards were granted as inducement awards under Nasdaq Listing Rule 5635(c)(4) and pursuant to the company's equity plan.

How many employees received inducement restricted stock units from BridgeBio (BBIO)?

Nine new employees received the restricted stock unit grants.

What equity plan governs the BridgeBio (BBIO) inducement grants and when was it amended?

The grants were made under the company's equity plan adopted in November 2019, amended and restated on February 10, 2023 and December 13, 2023.